Drugs / enzastaurin
enzastaurin
also known as
LY317615 · Enzastaurin Hydrochloride · DB-102 · Enzastaurin HCL · Enzastaurin monohydrochloride · Enzastaurina · Enzastaurine · Kinenza · +1 more
Small molecule targets PRKCB via inhibition
Trials 47 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT01432951 | Nov 2011 → Jan 2013 | cancer, lymphoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01388335 | Aug 2011 → Oct 2012 | cancer, lymphoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00516607 | Jul 2007 → Nov 2008 | central nervous system neoplasm | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | No outcome recorded |
| Phase 1 | NCT00503724 | Jun 2007 → May 2010 | central nervous system neoplasm, neuroblastoma | Pediatric Brain Tumor Consortium | Completed | No outcome recorded |
| Phase 1 | NCT00452257 | May 2007 → Sep 2008 | lymphoid leukemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01445119 | Jan 2007 → Jul 2013 | malignant glioma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00550927 | Nov 2006 → Mar 2010 | cancer of unknown primary site | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00108056 | Apr 2005 → Apr 2014 | glioma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00052273 | Dec 2002 → Nov 2004 | cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00452413 | May 2007 → Jul 2009 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/2 | NCT00402116 | Sep 2006 → Dec 2009 | gliosarcoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 234 trials | ||||||
| Phase 2 | NCT00744991 | Sep 2008 → Jan 2010 | primary cutaneous T-cell lymphoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00718419 | Jul 2008 → Sep 2010 | Waldenstrom macroglobulinemia, plasma cell myeloma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00709995 | Jun 2008 → Feb 2010 | renal cell carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00612586 | Feb 2008 → Jan 2010 | colorectal cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00414960 | Dec 2007 → Sep 2010 | lung cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00542919 | Nov 2007 → Mar 2010 | B-cell non-Hodgkin lymphoma, T-cell non-Hodgkin lymphoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00586508 | Nov 2007 → Oct 2013 | glioblastoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00536939 | Nov 2007 → Mar 2008 | breast cancer | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2 | NCT00533429 | Oct 2007 → Feb 2009 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00509821 | Oct 2007 → Feb 2010 | glioblastoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00530621 | Sep 2007 → Oct 2008 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00538681 | Sep 2007 → Nov 2008 | lung cancer | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2 | NCT00466440 | Jun 2007 → Aug 2009 | prostate cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00469976 | Jun 2007 → ? | lung cancer | Eastern Cooperative Oncology Group | Withdrawn | No outcome recorded |
| Phase 2 | NCT00451178 | May 2007 → Feb 2012 | lymphoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00475644 | May 2007 → Apr 2012 | follicular lymphoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00451555 | Apr 2007 → Dec 2010 | breast cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00437294 | Mar 2007 → Mar 2009 | breast cancer | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2 | NCT00437268 | Mar 2007 → May 2009 | colorectal carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00436280 | Feb 2007 → Nov 2009 | diffuse large B-cell lymphoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00420381 | Jan 2007 → May 2008 | carcinoma, ovarian cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00428714 | Jan 2007 → Jun 2009 | prostate cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00415363 | Dec 2006 → Jan 2011 | non-small cell lung carcinoma, small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00407758 | Nov 2006 → Aug 2016 | ovarian carcinoma, peritoneal carcinoma | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00391118 | Nov 2006 → Apr 2010 | fallopian tube neoplasm, ovarian cancer, peritoneal neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00386087 | Nov 2006 → Sep 2007 | breast cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00309140 | Mar 2006 → Jul 2009 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00308750 | Mar 2006 → Jul 2009 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00267020 | Dec 2005 → May 2008 | pancreatic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00192114 | Aug 2005 → Mar 2008 | colonic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00105092 | Mar 2005 → Feb 2007 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00088205 | Mar 2004 → May 2008 | mantle cell lymphoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00190723 | Oct 2002 → Dec 2006 | malignant glioma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00042666 | Jun 2002 → Sep 2008 | non-Hodgkin lymphoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00332202 | Jun 2006 → Apr 2013 | non-Hodgkin lymphoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00295815 | Jan 2006 → Aug 2007 | glioblastoma | Eli Lilly and Company | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00685633 Comparator | Dec 2008 → Jun 2010 | prostate cancer | Eastern Cooperative Oncology Group | Withdrawn | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05463679 Comparator | Jan → Jun 2025 | Ehlers-Danlos syndrome, vascular type | Aytu BioPharma, Inc. | Suspended | No outcome recorded |
| Phase 3 | NCT03776071 Comparator | Dec 2020 → Feb 2024 | glioblastoma | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 3 | NCT03263026 Comparator | Mar 2018 → Aug 2022 | diffuse large B-cell lymphoma | Denovo Biopharma LLC | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 53 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | enzastaurin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00420381 ↗49 |
| Known as | DB-102 | ChEMBL registry synonym — accepted as the source's own label CHEMBL300138 ↗ |
| Known as | Enzastaurin HCL | “Phase IIB Randomized, Placebo-Controlled, Double-Blind Study of Enzastaurin HCL (LY317615) for Lung Cancer Prevention in Former Smokers” NCT00414960 ↗ |
| Known as | Enzastaurin Hydrochloride | “Patients receive oral enzastaurin hydrochloride 3 times on day 1 and then once daily on days 2-28 of course 1.” NCT00407758 ↗2“Patients receive oral enzastaurin hydrochloride once or twice daily on days 1-28” NCT00516607 ↗ “Drug: Enzastaurin Hydrochloride” NCT03263026 ↗ |
| Known as | Enzastaurin monohydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL300138 ↗ |
| Known as | Enzastaurina | ChEMBL registry synonym — accepted as the source's own label CHEMBL300138 ↗ |
| Known as | Enzastaurine | ChEMBL registry synonym — accepted as the source's own label CHEMBL300138 ↗ |
| Known as | Kinenza | ChEMBL registry synonym — accepted as the source's own label CHEMBL300138 ↗ |
| Known as | LY-317615 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL300138 ↗ |
| Known as | LY317615 | “A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas” PMID 22291006 ↗ Jan 20124“Enzastaurin (LY317615) monohydronchloride” NCT00108056 ↗ “Enzastaurin (LY317615)” NCT01445119 ↗ “enzastaurin (LY317615)” NCT01388335 ↗ |
| Action | Inhibit | “blocking the enzymes necessary for cancer cell growth” NCT00052273 ↗1“Protein kinase C beta inhibitor” CHEMBL300138 ↗ |
| Modality | Small molecule | “Enzastaurin is a macrocyclic bisindolylmaleimide” NCT00108056 ↗ |
| Route | Oral | “500 mg, oral, QD, up to six 28 day cycles” NCT00042666 ↗ |
| Target | PRKCB | “Protein kinase C beta inhibitor” CHEMBL300138 ↗ |